Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3660810

CN(CCN)CCC(=O)O.O=C(O)C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.38
MEN1 O00255 1/20 0.38
KDM4C Q9H3R0 9/20 0.37
KDM5A P29375 7/20 0.37
LTA4H P09960 3/20 0.36
KDM5C P41229 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
HDAC3 O15379 2/20 0.35
HDAC4 P56524 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC7 Q8WUI4 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC10 Q969S8 2/20 0.35
HDAC11 Q96DB2 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
HDAC9 Q9UKV0 2/20 0.35
HDAC5 Q9UQL6 2/20 0.35
GABRR3 A8MPY1 1/20 0.35
GABRP O00591 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2560704 0.88 KMT2A (0.46) KMT2AMEN1KDM4CKDM5ALTA4H
SCHEMBL11435258 0.86 KMT2A (0.45) KMT2AMEN1KDM4CKDM5ALTA4H
Trifluoroacetic Acid SCHEMBL4552800 0.81 CHRM2 (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL21048742 0.81 KMT2A (0.38) KMT2AMEN1KDM4CKDM5ALTA4H
Trifluoroacetic Acid SCHEMBL3559072 0.78 HTR5A (0.36) HDAC3HDAC4HDAC1HDAC7HDAC2
Trifluoroacetic Acid SCHEMBL3086474 0.77 KDM4C (0.45) KMT2AMEN1KDM4CKDM5AKDM5C
SCHEMBL718216 0.77 KMT2A (0.56) KMT2AMEN1KDM4CKDM5ALTA4H
SCHEMBL11439889 0.76 KMT2A (0.52) KMT2AMEN1KDM4CKDM5ALTA4H
Trifluoroacetic Acid SCHEMBL8201988 0.75 LMNA (0.48) KMT2AMEN1HDAC3HDAC4HDAC1
SCHEMBL11239382 0.75 KMT2A (0.54) KMT2AMEN1KDM4CKDM5ALTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217621-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2015-04-22 EP disclosed
US-8710000-B2 Insulin derivative NOVO NORDISK A/S (DK) 2014-04-29 US disclosed
US-20100279931-A1 Insulin Derivative NOVO NORDISK A/S 2010-11-04 US disclosed
EP-2217621-A1 INSULIN DERIVATIVE Novo Nordisk A/S (DK) 2010-08-18 EP disclosed
WO-2009060071-A1 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2009-05-14 WO disclosed
EP-2058330-A1 Insulin derivative NOVO NORDISK A/S (DK) 2009-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279931-A1 Insulin Derivative IAPP, INSR, GPR119 KMT2A 4687/4885MEN1 690/4885KDM4C 4457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.